Koizumi Wasaburo, Tanabe Satoshi, Imaizumi Hiroshi, Hibi Ken-ichi, Kida Mitsuhiro, Ohida Masahito, Okayasu Isao, Saigenji Katsunori
Department of Gastroenterology, East Hospital Kitasato University School of Medicine, 2-1-1 Asamizodai, Sagamihara-shi, Kanagawa 228-8520, Japan.
Hepatogastroenterology. 2003 Jan-Feb;50(49):293-6.
BACKGROUND/AIMS: We measured the levels of IgG antibody in patients treated for H. pylori infection using four commercially available ELISA (enzyme linked immunosorbent assay) kits.
A total of 37 patients with peptic ulcers (21 patients had gastric ulcers and 16 patients had duodenal ulcers) were treated and monitored. These patients were treated for 14 days with either a dual therapy regime consisting of amoxicillin at 1,500 mg per day and omeprazole at 20 mg per day or a triple therapy regime consisting of the same medications as above plus metronidazole at 1,000 mg per day. Of these 37 patients, 24 patients (64.9%) had successful eradication of the H. pylori infection. The other 13 patients (35.5%) remained infected. Infection by H. pylori was confirmed prior to treatment using conventional microbiological (rapid urease test) and histological tests on biopsy specimens obtained by endoscopy. Four commercially available ELIZA kits (GAP-IgG, Hel-P, Helico-G and HM-CAP) were used to measure the serum levels of IgG antibody against H. pylori before treatment and at 3, 6 and 9 months after treatment. A significant decrease in the IgG titer was observed with the successful eradication of the H. pylori infection.
In patients whom the H. pylori infection was not eradicated, the IgG titer remained the same throughout the testing period. All the kits showed a significant decrease in the IgG levels (approximately 50% at 3 months) with patients that were successfully treated. The HM-CAP kit had the lowest sensitivity at detection the decrease in antibody levels (approximately 42% decrease at 3 months). The GAP-IgG kit was able to detect whether or not H. pylori was eradicated in shortest time period (100% uniformity ratio at 3 months).
The results of this study suggest that monitoring serum IgG levels after treatment may provide an early indicator of the efficacy of therapy in eradicating H. pylori infection. Additionally, the serum IgG level can provide evidence of infection in chronic gastritis patients even when the biopsy specimens are negative by microbiological and/or histological tests.
背景/目的:我们使用四种市售酶联免疫吸附测定(ELISA)试剂盒,对接受幽门螺杆菌感染治疗的患者的IgG抗体水平进行了测量。
总共37例消化性溃疡患者(21例胃溃疡患者和16例十二指肠溃疡患者)接受治疗并进行监测。这些患者接受了为期14天的治疗,治疗方案为:每日服用1500毫克阿莫西林和20毫克奥美拉唑的双联疗法,或上述相同药物加每日1000毫克甲硝唑的三联疗法。在这37例患者中,24例(64.9%)成功根除幽门螺杆菌感染。另外13例(35.5%)仍处于感染状态。在治疗前,通过常规微生物学(快速尿素酶试验)和对通过内镜检查获得的活检标本进行组织学检查,确认幽门螺杆菌感染。使用四种市售ELISA试剂盒(GAP-IgG、Hel-P、Helico-G和HM-CAP)在治疗前以及治疗后3、6和9个月测量血清中抗幽门螺杆菌IgG抗体水平。随着幽门螺杆菌感染的成功根除,观察到IgG滴度显著下降。
在未根除幽门螺杆菌感染的患者中,IgG滴度在整个检测期间保持不变。所有试剂盒均显示,成功治疗的患者IgG水平显著下降(3个月时约下降50%)。HM-CAP试剂盒在检测抗体水平下降方面的灵敏度最低(3个月时下降约42%)。GAP-IgG试剂盒能够在最短时间内检测出幽门螺杆菌是否被根除(3个月时一致性率为100%)。
本研究结果表明,治疗后监测血清IgG水平可能为根除幽门螺杆菌感染治疗的疗效提供早期指标。此外,即使活检标本的微生物学和/或组织学检测呈阴性,血清IgG水平也可为慢性胃炎患者的感染提供证据。